VIDAZA

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug VIDAZA contains one active pharmaceutical ingredient (API):

1 Azacitidine UNII M801H13NRU - AZACITIDINE

Azacitidine is believed to exert its antineoplastic effects by multiple mechanisms including cytotoxicity on abnormal haematopoietic cells in the bone marrow and hypomethylation of DNA. The cytotoxic effects of azacitidine may result from multiple mechanisms, including inhibition of DNA, RNA and protein synthesis, incorporation into RNA and DNA, and activation of DNA damage pathways. Read about Azacitidine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VIDAZA Powder for suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01BC07	Azacitidine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 6100C, 6138C, 9597D, 9598E
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 533200701159317
Country: CA	Health Products and Food Branch	Identifier(s): 02336707
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 360160512
Country: EE	Ravimiamet	Identifier(s): 1390968
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 08488001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 170986
Country: FR	Base de données publique des médicaments	Identifier(s): 61118337
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 152368
Country: HK	Department of Health Drug Office	Identifier(s): 55407
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 7338
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291419D1026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1035905
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 046M2013
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 88692
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 13789
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100205420
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68131001
Country: SG	Health Sciences Authority	Identifier(s): 13801P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 13483011H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699538774815
Country: US	FDA, National Drug Code	Identifier(s): 59572-102
Country: ZA	Health Products Regulatory Authority	Identifier(s): A40/26/0521